Large labs hold nuggets, which are not always exploited to their full potential.
This is the postulate of Noema, a biotech created last year from four molecules from Roche.
One of its founders, George Garibaldi, former head of neuroscience at the Swiss laboratory, bet that these “drug candidates”, which no longer corresponded to Roche's strategic priorities, could experience a second life.
Initially developed in psychiatry, these molecules could treat certain orphan neurological diseases (Gilles de la Tourette, etc.).
That is to say a potential market of one billion euros by cumulating all the indications.
In the light of scientific publications, he convinced Sofinnova Partners, one of the European leaders in venture capital specializing in life sciences.
Save time and money
Noema is not the first biotech to have been built from old molecules.
When clinical trials are not progressing fast enough or when candidates
This article is for subscribers only.
You have 70% left to discover.
Subscribe: 1 € the first month
Can be canceled at any time
I ENJOY IT